慢性心力衰竭治疗现状  

Current Opinion in Heart Failure Treatment

作　　者：唐炯[1] 燕纯伯[1] 

机构地区：[1]成都市第三人民医院心内科 成都市心血管病研究所,四川成都610031

出　　处：《心血管病学进展》2005年第6期569-572,共4页Advances in Cardiovascular Diseases

摘　　要：在心力衰竭多药物治疗的现实情况下,有必要探讨各种阻断肾素-血管紧张素-醛固酮系统药物的使用时机及联合使用问题,近期的CHARM试验提供了许多有价值的信息。尽管在心力衰竭总人群中具有β2、α受体阻滞作用的β受体阻滞剂是否更有改善生存率的优势仍在继续争论,但在包含了不同临床特点的亚组人群中应注意不同β-阻滞剂间的差异。现阶段如何进一步改善心力衰竭预后是一个非常具有挑战性的现实课题,根据病人临床特点实施个体化治疗,调整使用药物的传统顺序与组合,或者采用双室起搏等非药物的方法,是目前具有可行性的解决方案。In the currently established multidrug regimen of heart failure patients,considerable debate still exists about when to intensify the RASS antagonism therapy,and what is the optimal combination might be. CHARM study provides answers to some of these critical questions now. Although whether β2 .and et antagonism confer additional mortality benefit remains uncertain. It should not be assumed that all β-blocker agents are equivalent. How to further improve prognoses based on the established therapy is an extremely challenging question to be answered. Possible solutions can be done by individual treatment, changing the order of drug treatment instead of the conventional approach, or by nonpharmacological therapy（ the use of CRT and soon）.

关 键 词：心力衰竭 Β阻滞剂 肾素-血管紧张素-醛固酮系统 心脏再同步治疗 

分 类 号：R541.6[医药卫生—心血管疾病]